TY - JOUR
T1 - Molecular mechanisms of action of naringenin in chronic airway diseases
AU - Chin, Li Hian
AU - Hon, Chian Ming
AU - Chellappan, Dinesh Kumar
AU - Chellian, Jestin
AU - Madheswaran, Thiagarajan
AU - Zeeshan, Farrukh
AU - Awasthi, Rajendra
AU - Aljabali, Alaa Aa.
AU - Tambuwala, Murtaza M.
AU - Dureja, Harish
AU - Negi, Poonam
AU - Kapoor, Deepak N.
AU - Goyal, Rohit
AU - Paudel, Keshav Raj
AU - Satija, Saurabh
AU - Gupta, Gaurav
AU - Hsu, Alan
AU - Wark, Peter
AU - Mehta, Meenu
AU - Wadhwa, Ridhima
AU - Hansbro, Philip Michael
AU - Dua, Kamal
PY - 2020/7/15
Y1 - 2020/7/15
N2 - Chronic airway inflammatory diseases are characterized by persistent proinflammatory responses in the respiratory tract. Although, several treatment strategies are currently available, lifelong therapy is necessary for most of these diseases. In recent years, phytophenols, namely, flavonoids, derived from fruits and vegetables have been gaining tremendous interest and have been extensively studied due to their low toxicological profile. Naringenin is a bioflavonoid abundantly found in citrus fruits. This substance has shown notable therapeutic potential in various diseases due to its promising diverse biological activities. In this review, we have attempted to review the published studies from the available literature, discussing the molecular level mechanisms of naringenin in different experimental models of airway inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis. Current evidences have proposed that the anti-inflammatory properties of naringenin play a major role in ameliorating inflammatory disease states. In addition, naringenin also possesses several other biological properties. Despite the proposed mechanisms suggesting remarkable therapeutic benefits, the clinical use of naringenin is, however, hampered by its low solubility and bioavailability. Furthermore, this review also discusses on the studies that utilise nanocarriers as a drug delivery system to address the issue of poor solubility.
AB - Chronic airway inflammatory diseases are characterized by persistent proinflammatory responses in the respiratory tract. Although, several treatment strategies are currently available, lifelong therapy is necessary for most of these diseases. In recent years, phytophenols, namely, flavonoids, derived from fruits and vegetables have been gaining tremendous interest and have been extensively studied due to their low toxicological profile. Naringenin is a bioflavonoid abundantly found in citrus fruits. This substance has shown notable therapeutic potential in various diseases due to its promising diverse biological activities. In this review, we have attempted to review the published studies from the available literature, discussing the molecular level mechanisms of naringenin in different experimental models of airway inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis. Current evidences have proposed that the anti-inflammatory properties of naringenin play a major role in ameliorating inflammatory disease states. In addition, naringenin also possesses several other biological properties. Despite the proposed mechanisms suggesting remarkable therapeutic benefits, the clinical use of naringenin is, however, hampered by its low solubility and bioavailability. Furthermore, this review also discusses on the studies that utilise nanocarriers as a drug delivery system to address the issue of poor solubility.
KW - Asthma
KW - Chronic airway inflammatory disease
KW - Chronic obstructive pulmonary disease
KW - Lung cancer
KW - Naringenin
KW - Pulmonary fibrosis
UR - https://www.ncbi.nlm.nih.gov/pubmed/32343971
UR - https://linkinghub.elsevier.com/retrieve/pii/S0014299920302314
UR - http://www.scopus.com/inward/record.url?scp=85084238920&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2020.173139
DO - 10.1016/j.ejphar.2020.173139
M3 - Article
C2 - 32343971
SN - 0014-2999
VL - 879
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
M1 - 173139
ER -